GlassScriptPhysician profile
Nathan Jon Neufeld
NPI 1497993067
$170,964.17
in general payments reported to CMS, 2019-2025
19 companies · $22K in 2025
The $22K reported for 2025 was more than what 96% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,251 · 2020: $377 · 2021: $7,161 · 2022: $51K · 2023: $52K · 2024: $35K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $36K · Travel and Lodging: $9,552 · Food and Beverage: $4,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,525.00 |
| Consulting Fee | $36,400.00 |
| Travel and Lodging | $9,552.39 |
| Food and Beverage | $4,118.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $126,864.32 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Osteocool Rf Ablation System |
| Stryker Corporation | $38,986.15 | 2022-2025 | Autoplex, Optablate, Avaflex |
| Medtronic USA, INC. | $4,322.93 | 2019-2020 | |
| Abbott Laboratories | $187.16 | 2020 | |
| Averitas Pharma INC. | $140.01 | 2023-2024 | Qutenza |
| Spr Therapeutics, INC | $81.21 | 2023 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $78.94 | 2025 | |
| Grt US Holding, INC. | $60.00 | 2022 | |
| Merck Sharp & Dohme LLC | $41.82 | 2021-2023 | Lynparza, Keytruda |
| Paratek Pharmaceuticals, INC. | $30.15 | 2019 | |
| Biotronik Nro, INC. | $26.58 | 2025 | Prospera |
| Collegium Pharmaceutical, INC. | $21.54 | 2025 | Xtampza |
| Eisai INC. | $21.29 | 2019 | |
| Flowonix Medical Incorporated | $20.87 | 2019 | |
| Daiichi Sankyo INC. | $19.61 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $17.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.98 | 2019 | |
| Acacia Pharma INC | $15.28 | 2021 | |
| Merit Medical Systems INC | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Neufeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.